Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer
- 15 February 1984
- Vol. 53 (4) , 844-852
- https://doi.org/10.1002/1097-0142(19840215)53:4<844::aid-cncr2820530405>3.0.co;2-n
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5-fluorouracil and dactinomycin or with the combination of cytoxan, 5-fluorouracil and dactinomycinCancer, 1980
- Advanced Ovarian AdenocarcinomaNew England Journal of Medicine, 1978
- Melphalan Chemotherapy in Advanced Ovarian CarcinomaObstetrics & Gynecology, 1978
- Management of Ovarian CarcinomaNew England Journal of Medicine, 1976
- Chemotherapy of advanced ovarian carcinoma: A prospective randomized comparison of phenylalanine mustard and high dose cyclophosphamideGynecologic Oncology, 1974
- Advanced ovarian cancer: Primary treatment with surgery, radiotherapy, and chemotherapyCancer, 1972
- Asymptotically Efficient Rank Invariant Test ProceduresJournal of the Royal Statistical Society. Series A (General), 1972
- Treatment of cancer with weekly intravenous 5-fluorouracil.Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG)Cancer, 1971
- Five Years Clinical Experience with 5-FluorouracilJAMA, 1962
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958